Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Significance: Narcolepsy-cataplexy is a debilitating disorder characterized by excessive daytime sleepiness (sleep attacks) and cataplexy, a sudden bilateral loss of muscle tone often triggered by emotion. The disease is caused by a selective loss of hypothalamic neurons producing the neuropeptide orexin. Currently, only symptomatic therapies are available for narcolepsy. Here, we examine the pharmacological effect of YNT-185, a nonpeptide, selective agonist for the orexin type-2 receptor in mouse models of narcolepsy-cataplexy. We show that peripheral administration of YNT-185 significantly ameliorates the narcolepsy symptoms in model mice, providing a proof-of-concept for the mechanistic treatment of narcolepsy with orexin receptor agonists. YNT-185 also promotes wakefulness in wild-type mice, suggesting that orexin receptor agonists may be useful for treating sleepiness due to other causes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501
Self-citationInternational Classification of Sleep Disorders-Third Edition
Sateia, M. J. (2014) · Chest · doi:10.1378/chest.14-0970 · Cited by 3,860 · cited 1×
“According to the clinical definition by the International Classification of Sleep Disorders-Third Edition, two types of narcoleptic disorders are categorized (7).”
MethodNeurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466 · cited 1×
“Orexin-producing neurons send axons diffusely through the central nervous system, with especially dense innervations to several nuclei involved in sleep/wakefulness regulation (2, 3).”
BackgroundNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 4×
“Murine models of narcolepsy-cataplexy include OXKO mice (2), orexin receptor-deficient (Hcrtr1;Hcrtr2, abbreviated as OXRDKO) mice, and the orexin/ataxin-3 transgenic mice (in which orexin neurons are genetically and postnatally ablated) (12).”
BackgroundInfluentialSelf-citationLin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81965-0 · Cited by 2,613 · cited 1×
“A crucial role of the orexin system in the regulation of sleep/ wakefulness was initially uncovered by the discovery that OX2Rdeficient dogs (6) and prepro-orexin knockout (Hcrt, abbreviated as OXKO) mice (2) exhibited symptoms resembling human narcolepsy-cataplexy.”
BackgroundReduced Number of Hypocretin Neurons in Human Narcolepsy
Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000) · Neuron · doi:10.1016/s0896-6273(00)00058-1 · Cited by 2,089
Hypocretin (orexin) deficiency in human narcolepsy
Nishino, S., Ripley, B., Overeem, S., Lammers, G. J., & Mignot, E. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05582-8 · Cited by 1,776
Tsuneki, H., Tokai, E., Nakamura, Y., Takahashi, K., Fujita, M., Asaoka, T., Kon, K., Anzawa, Y., Wada, T., Takasaki, I., et al. (2015) · Diabetes · doi:10.2337/db14-0695 · Cited by 73 · cited 2×
“Indeed, daily active-phase administrations of orexin-A prevented hepatic insulin resistance via bidirectional regulation of the autonomic nervous system (26), whereas daily resting-phase administrations of suvorexant for 2–4 wk improved glucose tolerance in obese mice (27).”
BackgroundSelf-citation
Cited by
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment
Bassetti, C. L. A., Adamantidis, A., Burdakov, D., Han, F., Gay, S., Kallweit, U., Khatami, R., Koning, F., Kornum, B. R., Lammers, G. J., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0226-9 · Cited by 646
Self-citationThe neurobiological basis of narcolepsy
Mahoney, C. E., Cogswell, A., Koralnik, I. J., & Scammell, T. E. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0097-x · Cited by 289
Activation of orexin system facilitates anesthesia emergence and pain control
Zhou, W., Cheung, K., Kyu, S., Wang, L., Guan, Z., Kurien, P. A., Bickler, P. E., & Jan, L. Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808622115 · Cited by 81
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00311 · Cited by 18
Metadata
- Authors
- Irukayama-Tomobe, Y., Ogawa, Y., Tominaga, H., Ishikawa, Y., Hosokawa, N., Ambai, S., Kawabe, Y., Uchida, S., Nakajima, R., Saitoh, T., Kanda, T., Vogt, K., Sakurai, T., Nagase, H., & Yanagisawa, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2017-05-15
- Volume
- 114
- Issue
- 22
- Pages
- 5731-5736
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2616546946
- Cited by
- 140
- References
- 8
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. https://app.cochat.ai/papers/10.1073/pnas.1700499114
- The paper
- Irukayama-Tomobe, Y., Ogawa, Y., Tominaga, H., Ishikawa, Y., Hosokawa, N., Ambai, S., Kawabe, Y., Uchida, S., Nakajima, R., Saitoh, T., Kanda, T., Vogt, K., Sakurai, T., Nagase, H., & Yanagisawa, M. (2017). Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1700499114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.